Pontifax
About
Founded in 2004, Pontifax is a healthcare-dedicated venture capital firm with over $350 million under management. We seek transformative, cutting-edge life sciences technologies at all development stages. Our portfolio comprises over 40 companies that develop breakthrough solutions to substantial unmet needs.
Key facts
At-a-glance profile data
- Website
- pontifax.com
- Type
- Venture Capital
- Headquarters
- Tel Aviv, Israel
- Funds raised
- $620M
- Portfolio companies
- 59
- Stages
- Series ASeries BSeries C
- Cheque size
- $2M to $200M
- Sector focus
- HealthcareDrug DevelopmentGenomicsNext Generation SequencingBiotech
Recent investments
| Date | Company | Round | Amount |
|---|---|---|---|
| 7 Jul 2026 | FORE Biotherapeutics | Series D-2 Extension | $67M |
| 14 Apr 2026 | Adcendo | Series C | $75M |
| 7 Oct 2025 | Adicet Bio | Registered Direct Offering | $80M |
| 28 Jan 2025 | Lutris Pharma | Series A | $30M |
| 25 Nov 2024 | Adcendo | Series B | $135M |
| 17 Jul 2024 | CytoReason | Series B | $80M |
| 24 Jun 2024 | 901333 | Seed | $10M |
| 25 Jan 2024 | Adicet Bio | Follow-on Offering | $98M |
| 23 Aug 2023 | 80073 | Series D | $75M |
| 20 Jul 2023 | CytoReason | Debt | $16M |
Add first review
Frequently asked
What companies has Pontifax invested in?
Pontifax has invested in FORE Biotherapeutics, Adcendo, Adicet Bio, Lutris Pharma, CytoReason and 54 more.
Founders (1)